The Study
Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer’s disease
This study watched a group of older people who already had early signs of Alzheimer’s brain changes and saw which ones got worse over time. It found that people with both high levels of a protein in their blood and visible tau on brain scans tended to decline faster — but it didn’t make anyone change their treatment, so we can’t say the protein or scan caused the decline.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Scientists tested two ways to spot early Alzheimer’s changes: a blood test for a protein called p-tau217 and a brain scan (tau-PET). They found that people with both markers high were much more likely to lose brain tissue and memory quickly.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 565 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this means doctors could use these two tests together to find the people at highest risk of developing dementia soon, so they can be prioritized for early treatments.
- 2Among people with amyloid buildup, those with both high p-tau217 and positive tau-PET had 9.98x higher risk of advancing to severe Alzheimer’s biology and 3.03x higher risk of memory loss over 5 years.
- 3Those with only one marker high progressed much slower.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Alzheimer's Research & Therapy
Year
2026
Authors
M. Labrador-Espinosa, N. Franzmeier, Stamatia Karagianni, Alexis Moscoso, Michael Schöll
Related Content
Claims (6)
Older adults without cognitive impairment but with amyloid-beta buildup who have high levels of p-tau217 in their blood and visible tau deposits in brain scans show the fastest increase in tau tangles, greatest loss of gray matter in key brain regions, and quickest decline in thinking skills over five years.
In people without cognitive symptoms but with amyloid-beta buildup in the brain, those with both high levels of p-tau217 in the blood and positive tau-PET scans have nearly 10 times greater risk of advancing to later Alzheimer’s disease stages and three times greater risk of developing cognitive impairment within five years compared to those without either biomarker abnormality.
Among people with early Alzheimer’s brain changes but no cognitive symptoms, those with mismatched biomarker results (high p-tau217 in blood but no tau buildup on PET scan, or vice versa) show slower progression of tau accumulation, brain cell loss, and memory decline than those with matching biomarker abnormalities.
In people with early brain changes linked to Alzheimer's but no cognitive symptoms, the buildup of tau protein and brain tissue loss are directly linked to worsening memory and thinking, while amyloid buildup is not.
When doctors visually read tau-PET brain scans using standard criteria, they may fail to detect early tau buildup in people with high levels of p-tau217 in their blood, and more precise measurement methods are needed to correctly identify those at risk.
Phosphorylated tau protein can be detected in the brain using neuroimaging techniques 12 years before a person shows any signs of Alzheimer's disease.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.